BCL6 promotes glioma and serves as a therapeutic target

Liang Xu, Ye Chen, Marina Dutra-Clarke, Anand Mayakonda, Masaharu Hazawa, Steve E. Savinoff, Ngan Doan, Jonathan W. Said, William H. Yong, Ashley Watkins, Henry Yang, Ling Wen Ding, Yan Yi Jiang, Jeffrey Tyner, Jianhong Ching, Jean Paul Kovalik, Vikas Madan, Shing Leng Chan, Markus Müschen, Joshua J. Breunig & 3 others De Chen Lin, H. Phillip Koeffler, Webster K. Cavenee

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

ZBTB transcription factors orchestrate gene transcription during tissue development. However, their roles in glioblastoma (GBM) remain unexplored. Here, through a functional screening of ZBTB genes, we identify that BCL6 is required for GBM cell viability and that BCL6 overexpression is associated with worse prognosis. In a somatic transgenic mouse model, depletion of Bcl6 inhibits the progression of KrasG12V-driven high-grade glioma. Transcriptome analysis demonstrates the involvement of BCL6 in tumor protein p53 (TP53), erythroblastic leukemia viral oncogene homolog (ErbB), and MAPK signaling pathways. Indeed, BCL6 represses the expression of wild-type p53 and its target genes in GBM cells. Knockdown of BCL6 augments the activation of TP53 pathway in response to radiation. Importantly, we discover that receptor ty-rosine kinase AXL is a transcriptional target of BCL6 in GBM and mediates partially the regulatory effects of BCL6 on both MEK-ERK (mitogen-activated protein/extracellular signal-regulated kinase kinase-extracellular signal-regulated kinase) and S6K-RPS6 (ribosomal protein S6 kinase-ribosomal protein S6) axes. Similar to BCL6 silencing, depletion of AXL profoundly attenuates GBM proliferation both in vitro and in vivo. Moreover, targeted inhibition of BCL6/nuclear receptor corepressor 1 (NCoR) complex by peptidomimetic inhibitor not only significantly decreases AXL expression and the activity of MEK-ERK and S6K-RPS6 cascades but also displays a potent antipro-liferative effect against GBM cells. Together, these findings uncover a glioma-promoting role of BCL6 and provide the rationale of targeting BCL6 as a potential therapeutic approach.

Original languageEnglish (US)
JournalProceedings of the National Academy of Sciences of the United States of America
Volume114
Issue number15
DOIs
StatePublished - 2017

Fingerprint

Glioblastoma
Glioma
Ribosomal Protein S6
Ribosomal Protein S6 Kinases
Mitogen-Activated Protein Kinase Kinases
Extracellular Signal-Regulated MAP Kinases
Phosphotransferases
Therapeutics
Genes
Peptidomimetics
Co-Repressor Proteins
Proteins
Gene Expression Profiling
Mitogens
Oncogenes
Transgenic Mice
Neoplasms
Cell Survival
Leukemia
Transcription Factors

Keywords

  • AXL
  • BCL6
  • Glioblastoma multiforme
  • NCoR
  • ZBTB

ASJC Scopus subject areas

  • General

Cite this

Xu, L., Chen, Y., Dutra-Clarke, M., Mayakonda, A., Hazawa, M., Savinoff, S. E., ... Cavenee, W. K. (2017). BCL6 promotes glioma and serves as a therapeutic target. Proceedings of the National Academy of Sciences of the United States of America, 114(15). https://doi.org/10.1073/pnas.1609758114

BCL6 promotes glioma and serves as a therapeutic target. / Xu, Liang; Chen, Ye; Dutra-Clarke, Marina; Mayakonda, Anand; Hazawa, Masaharu; Savinoff, Steve E.; Doan, Ngan; Said, Jonathan W.; Yong, William H.; Watkins, Ashley; Yang, Henry; Ding, Ling Wen; Jiang, Yan Yi; Tyner, Jeffrey; Ching, Jianhong; Kovalik, Jean Paul; Madan, Vikas; Chan, Shing Leng; Müschen, Markus; Breunig, Joshua J.; Lin, De Chen; Koeffler, H. Phillip; Cavenee, Webster K.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 114, No. 15, 2017.

Research output: Contribution to journalArticle

Xu, L, Chen, Y, Dutra-Clarke, M, Mayakonda, A, Hazawa, M, Savinoff, SE, Doan, N, Said, JW, Yong, WH, Watkins, A, Yang, H, Ding, LW, Jiang, YY, Tyner, J, Ching, J, Kovalik, JP, Madan, V, Chan, SL, Müschen, M, Breunig, JJ, Lin, DC, Koeffler, HP & Cavenee, WK 2017, 'BCL6 promotes glioma and serves as a therapeutic target', Proceedings of the National Academy of Sciences of the United States of America, vol. 114, no. 15. https://doi.org/10.1073/pnas.1609758114
Xu, Liang ; Chen, Ye ; Dutra-Clarke, Marina ; Mayakonda, Anand ; Hazawa, Masaharu ; Savinoff, Steve E. ; Doan, Ngan ; Said, Jonathan W. ; Yong, William H. ; Watkins, Ashley ; Yang, Henry ; Ding, Ling Wen ; Jiang, Yan Yi ; Tyner, Jeffrey ; Ching, Jianhong ; Kovalik, Jean Paul ; Madan, Vikas ; Chan, Shing Leng ; Müschen, Markus ; Breunig, Joshua J. ; Lin, De Chen ; Koeffler, H. Phillip ; Cavenee, Webster K. / BCL6 promotes glioma and serves as a therapeutic target. In: Proceedings of the National Academy of Sciences of the United States of America. 2017 ; Vol. 114, No. 15.
@article{5853163438e743b8bc35a18a95e30b7e,
title = "BCL6 promotes glioma and serves as a therapeutic target",
abstract = "ZBTB transcription factors orchestrate gene transcription during tissue development. However, their roles in glioblastoma (GBM) remain unexplored. Here, through a functional screening of ZBTB genes, we identify that BCL6 is required for GBM cell viability and that BCL6 overexpression is associated with worse prognosis. In a somatic transgenic mouse model, depletion of Bcl6 inhibits the progression of KrasG12V-driven high-grade glioma. Transcriptome analysis demonstrates the involvement of BCL6 in tumor protein p53 (TP53), erythroblastic leukemia viral oncogene homolog (ErbB), and MAPK signaling pathways. Indeed, BCL6 represses the expression of wild-type p53 and its target genes in GBM cells. Knockdown of BCL6 augments the activation of TP53 pathway in response to radiation. Importantly, we discover that receptor ty-rosine kinase AXL is a transcriptional target of BCL6 in GBM and mediates partially the regulatory effects of BCL6 on both MEK-ERK (mitogen-activated protein/extracellular signal-regulated kinase kinase-extracellular signal-regulated kinase) and S6K-RPS6 (ribosomal protein S6 kinase-ribosomal protein S6) axes. Similar to BCL6 silencing, depletion of AXL profoundly attenuates GBM proliferation both in vitro and in vivo. Moreover, targeted inhibition of BCL6/nuclear receptor corepressor 1 (NCoR) complex by peptidomimetic inhibitor not only significantly decreases AXL expression and the activity of MEK-ERK and S6K-RPS6 cascades but also displays a potent antipro-liferative effect against GBM cells. Together, these findings uncover a glioma-promoting role of BCL6 and provide the rationale of targeting BCL6 as a potential therapeutic approach.",
keywords = "AXL, BCL6, Glioblastoma multiforme, NCoR, ZBTB",
author = "Liang Xu and Ye Chen and Marina Dutra-Clarke and Anand Mayakonda and Masaharu Hazawa and Savinoff, {Steve E.} and Ngan Doan and Said, {Jonathan W.} and Yong, {William H.} and Ashley Watkins and Henry Yang and Ding, {Ling Wen} and Jiang, {Yan Yi} and Jeffrey Tyner and Jianhong Ching and Kovalik, {Jean Paul} and Vikas Madan and Chan, {Shing Leng} and Markus M{\"u}schen and Breunig, {Joshua J.} and Lin, {De Chen} and Koeffler, {H. Phillip} and Cavenee, {Webster K.}",
year = "2017",
doi = "10.1073/pnas.1609758114",
language = "English (US)",
volume = "114",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "15",

}

TY - JOUR

T1 - BCL6 promotes glioma and serves as a therapeutic target

AU - Xu, Liang

AU - Chen, Ye

AU - Dutra-Clarke, Marina

AU - Mayakonda, Anand

AU - Hazawa, Masaharu

AU - Savinoff, Steve E.

AU - Doan, Ngan

AU - Said, Jonathan W.

AU - Yong, William H.

AU - Watkins, Ashley

AU - Yang, Henry

AU - Ding, Ling Wen

AU - Jiang, Yan Yi

AU - Tyner, Jeffrey

AU - Ching, Jianhong

AU - Kovalik, Jean Paul

AU - Madan, Vikas

AU - Chan, Shing Leng

AU - Müschen, Markus

AU - Breunig, Joshua J.

AU - Lin, De Chen

AU - Koeffler, H. Phillip

AU - Cavenee, Webster K.

PY - 2017

Y1 - 2017

N2 - ZBTB transcription factors orchestrate gene transcription during tissue development. However, their roles in glioblastoma (GBM) remain unexplored. Here, through a functional screening of ZBTB genes, we identify that BCL6 is required for GBM cell viability and that BCL6 overexpression is associated with worse prognosis. In a somatic transgenic mouse model, depletion of Bcl6 inhibits the progression of KrasG12V-driven high-grade glioma. Transcriptome analysis demonstrates the involvement of BCL6 in tumor protein p53 (TP53), erythroblastic leukemia viral oncogene homolog (ErbB), and MAPK signaling pathways. Indeed, BCL6 represses the expression of wild-type p53 and its target genes in GBM cells. Knockdown of BCL6 augments the activation of TP53 pathway in response to radiation. Importantly, we discover that receptor ty-rosine kinase AXL is a transcriptional target of BCL6 in GBM and mediates partially the regulatory effects of BCL6 on both MEK-ERK (mitogen-activated protein/extracellular signal-regulated kinase kinase-extracellular signal-regulated kinase) and S6K-RPS6 (ribosomal protein S6 kinase-ribosomal protein S6) axes. Similar to BCL6 silencing, depletion of AXL profoundly attenuates GBM proliferation both in vitro and in vivo. Moreover, targeted inhibition of BCL6/nuclear receptor corepressor 1 (NCoR) complex by peptidomimetic inhibitor not only significantly decreases AXL expression and the activity of MEK-ERK and S6K-RPS6 cascades but also displays a potent antipro-liferative effect against GBM cells. Together, these findings uncover a glioma-promoting role of BCL6 and provide the rationale of targeting BCL6 as a potential therapeutic approach.

AB - ZBTB transcription factors orchestrate gene transcription during tissue development. However, their roles in glioblastoma (GBM) remain unexplored. Here, through a functional screening of ZBTB genes, we identify that BCL6 is required for GBM cell viability and that BCL6 overexpression is associated with worse prognosis. In a somatic transgenic mouse model, depletion of Bcl6 inhibits the progression of KrasG12V-driven high-grade glioma. Transcriptome analysis demonstrates the involvement of BCL6 in tumor protein p53 (TP53), erythroblastic leukemia viral oncogene homolog (ErbB), and MAPK signaling pathways. Indeed, BCL6 represses the expression of wild-type p53 and its target genes in GBM cells. Knockdown of BCL6 augments the activation of TP53 pathway in response to radiation. Importantly, we discover that receptor ty-rosine kinase AXL is a transcriptional target of BCL6 in GBM and mediates partially the regulatory effects of BCL6 on both MEK-ERK (mitogen-activated protein/extracellular signal-regulated kinase kinase-extracellular signal-regulated kinase) and S6K-RPS6 (ribosomal protein S6 kinase-ribosomal protein S6) axes. Similar to BCL6 silencing, depletion of AXL profoundly attenuates GBM proliferation both in vitro and in vivo. Moreover, targeted inhibition of BCL6/nuclear receptor corepressor 1 (NCoR) complex by peptidomimetic inhibitor not only significantly decreases AXL expression and the activity of MEK-ERK and S6K-RPS6 cascades but also displays a potent antipro-liferative effect against GBM cells. Together, these findings uncover a glioma-promoting role of BCL6 and provide the rationale of targeting BCL6 as a potential therapeutic approach.

KW - AXL

KW - BCL6

KW - Glioblastoma multiforme

KW - NCoR

KW - ZBTB

UR - http://www.scopus.com/inward/record.url?scp=85018484251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018484251&partnerID=8YFLogxK

U2 - 10.1073/pnas.1609758114

DO - 10.1073/pnas.1609758114

M3 - Article

VL - 114

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 15

ER -